InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and...
Looks like a great buying opportunity, the stock looks highly oversold, with a short term spike in volatility, this could be a good candidates for a mind to long term bull run and considering the new report on the benefits of cannabinoids.
InMed Pharmaceuticals produced an absolutely monster gap that now needs to be worked backwards in these very bearish circumstances. Fibs give some initial goals. Negative momentum loop done. The pull out will on a divergence or completion of Fibgoals, whichever occurs first.
Goals 0.56, 0.49. Invalidation at 0.89.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that...
test
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research and development of novel. It also involves in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981...
recently rejected at resistance, but if it breaks we know what will happen... a test of 7 and 50 percent run that day! just like pola did with it broke top trendline resistance friday! we just missed that one :( next time! good luck longs ! have a great marthin luther king jr day tomorrow <3
